Hims & Hers: The Bull Case Remains Strong

Hims & Hers is described as attractive at $33, supported by a renewed Novo Nordisk partnership, unique access to patient demand, and international expansion. Near-term fundamentals remain weak, with Q1 2026 revenue growth of just 4%, declining margins, and a net loss, but management is targeting more than $6.5B in revenue and $1.3B+ in adjusted EBITDA by 2030. The article argues valuation can be justified if retention and cross-sell improve.

Analysis

The renewed platform relationship is more important than the headline growth print because it reduces a key distribution-risk overhang: if Hims can keep a premium supplier aligned, it preserves access to a high-intent cohort that is expensive to reacquire through paid channels. The second-order winner is likely NVO, which gets a broader consumer funnel and a lower-friction path to prescription conversion without bearing the full customer-acquisition cost. The loser set is the fragmented telehealth/weight-loss cohort that lacks either brand trust or supply credibility; those names will now have to spend more on marketing while facing a more differentiated incumbent.

The market is probably still underpricing the duration of the margin reset. Near-term profitability can stay pressured for several quarters if the company is deliberately using pricing and expansion to buy retention and cross-sell, but that can be rational if it improves cohort value over a 12-24 month horizon. The key catalyst is not the next quarter's revenue line; it is whether repeat purchase rates and category attach rates move high enough to make the 2030 target look mechanically achievable. If those metrics inflect, the stock can re-rate well before GAAP earnings do.

The contrarian view is that investors may be extrapolating consumer-like multiple expansion onto a business that still carries regulatory, supply, and channel concentration risk. A 4% growth rate with weakening margins is usually not what supports a premium multiple unless there is clear evidence of durable customer economics. The setup works only if management can prove that international rollout and diversified categories are not just top-line fillers but actually improve lifetime value and reduce churn; otherwise this remains a classic story-stock where sentiment outruns fundamentals.

Key Decisions for Investors

• Long HIMS on weakness into the next 2-6 weeks, but only as a measured position: upside is a re-rating if retention/cross-sell data improves; downside is multiple compression if margins continue to deteriorate. Use a tight stop if management commentary suggests slower cohort quality than expected.
• Overweight NVO vs. HIMS in a relative-value framework over the next 3-6 months: the partnership lowers customer-acquisition friction for NVO while HIMS still bears execution risk. Favor the side with less dependence on execution for the same thematic exposure.
• Buy HIMS call spreads 3-6 months out rather than common stock if you want convexity into a potential retention-inflection catalyst. Risk/reward improves if the market starts pricing the 2030 target before GAAP profitability arrives.
• Avoid chasing after a sharp gap-up; wait for post-earnings or post-commentary drift to establish positions. This name can retrace hard if the market decides the margin compression is structural rather than temporary.